Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rib-X Counting On Rational Drug Design To Outsmart Resistant Bacteria

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Three years after creating its RX-04 discovery platform, Rib-X Pharmaceuticals Inc. has vetted 1,400 compounds, tuned them for efficacy against multi-drug resistant bacteria, and is in the process of selecting a handful of candidates to prep for an IND in 2012.

You may also be interested in...



Re-Named Melinta Moving Ahead With Delafloxacin And Novel Class Of Antibiotics

Formerly known as Rib-X Pharmaceuticals, Connecticut biotech reacquires rights to RX-04 antibiotic platform from Sanofi and moves forward with venture backing from Vatera and new management team.

Antibiotic Legislation Offers Big GAIN For Small Firm: Rib-X Extends Delafloxacin Exclusivity

Rib-X is among the first to take advantage of the Generating Antibiotic Incentives Now provisions of the FDA reauthorization legislation with five years’ extra exclusivity for its lead broad spectrum antibiotic candidate, a next-generation fluoroquinolone. Designation for the program came swiftly, company says.

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2011

Biopharma financing dropped in Q3 2011 to $1.3 billion, down from $6.3 billion in Q2. There were 20 M&A deals that totaled $30.9 billion, attributed mainly to the $27.7 million merger of PBMs Express Scripts and Medco. Almost a quarter of the alliances penned were for preclinical assets.

Related Content

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel